{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:26:44Z","timestamp":1762342004431},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bladder cancer is a common malignant tumor of the genitourinary system, with the primary cause of death being metastasis. The most common metastatic sites are the lymph nodes, liver, lung, bone, peritoneum, pleura, kidney, adrenal gland, and the intestine. Brain and heart metastases are rare. In this report, we describe a patient who had pulmonary lymph node metastases more than a year after being diagnosed with bladder cancer, followed by brain and cardiac metastases more than two years later. Following the failure of standard first-line chemotherapy, the patient accepted 6 cycles of tislelizumab immunotherapy. The re-examination revealed that the bilateral frontal brain metastases had vanished, the right temporal lobe metastases had been greatly decreased, the neurological symptoms had been alleviated, and the cardiac metastases had disappeared. This is a rare clinical case with encouraging effects of tislelizumab and can serve as a model for the treatment of similar patients.<\/jats:p>","DOI":"10.1186\/s12957-022-02876-9","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:02:33Z","timestamp":1671415353000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A rare case of bladder cancer that metastasized to brain, heart, and lung lymph nodes benefited from immunotherapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Lian-kai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2876_CR1","first-page":"293","volume":"43","author":"HZ Li","year":"2021","unstructured":"Li HZ, Zheng RS, Du LB, et al. Bladder cancer incidence, mortality and temporal trends in China. Zhonghua Zhong Liu Za Zhi. 2021;43:293\u20138.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2876_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2876_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000030361","volume":"62","author":"A Wallmeroth","year":"1999","unstructured":"Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int. 1999;62:69\u201375.","journal-title":"Urol Int"},{"key":"2876_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/A:1005918508317","volume":"39","author":"RE Clatterbuck","year":"1998","unstructured":"Clatterbuck RE, Sampath P, Olivi A. Transitional cell carcinoma presenting as a solitary brain lesion: a case report and review of the world literature. J Neuro-Oncol. 1998;39:91\u20134.","journal-title":"J Neuro-Oncol"},{"key":"2876_CR5","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1016\/j.clgc.2019.11.008","volume":"18","author":"LN Diamantopoulos","year":"2020","unstructured":"Diamantopoulos LN, Khaki AR, Sonpavde GP, et al. Central nervous system metastasis in patients with urothelial carcinoma: Institutional experience and a comprehensive review of the literature. Clin Genitourin Cancer. 2020;18:e266\u2013e76.","journal-title":"Clin Genitourin Cancer"},{"key":"2876_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/S0022-5347(05)64996-8","volume":"167","author":"AS Mahmoud-Ahmed","year":"2002","unstructured":"Mahmoud-Ahmed AS, Suh JH, Kupelian PA, et al. Brain metastases from bladder carcinoma: presentation, treatment and survival. J Urol. 2002;167:2419\u201322.","journal-title":"J Urol"},{"key":"2876_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0022-5347(17)36123-2","volume":"149","author":"M Rosenstein","year":"1993","unstructured":"Rosenstein M, Wallner K, Scher H, Sternberg CN. Treatment of brain metastases from bladder cancer. J Urol. 1993;149:480\u20133.","journal-title":"J Urol"},{"key":"2876_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-017-0748-7","volume":"77","author":"MS Farina","year":"2017","unstructured":"Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in urothelial cancer: Recent results and future perspectives. Drugs. 2017;77:1077\u201389.","journal-title":"Drugs."},{"key":"2876_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"2876_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"2876_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O'Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label study. JAMA Oncol. 2017;3:e172411.","journal-title":"JAMA Oncol"},{"key":"2876_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748\u201357.","journal-title":"Lancet."},{"key":"2876_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51\u201364.","journal-title":"Lancet Oncol"},{"key":"2876_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102360","volume":"104","author":"A Martini","year":"2022","unstructured":"Martini A, Raggi D, Fallara G, et al. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2022;104:102360.","journal-title":"Cancer Treat Rev"},{"key":"2876_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 2021;112:305\u201313.","journal-title":"Cancer Sci"},{"key":"2876_CR16","doi-asserted-by":"crossref","unstructured":"Lee A, Keam SJ. Tislelizumab: First Approval. Drugs. 2020;80(6):617\u201324.","DOI":"10.1007\/s40265-020-01286-z"},{"key":"2876_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2876_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14872","volume":"125","author":"A Martini","year":"2020","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020;125:270\u20135.","journal-title":"BJU Int"},{"key":"2876_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.010","volume":"505","author":"S Liu","year":"2021","unstructured":"Liu S, Chen X, Lin T. Lymphatic metastasis of bladder cancer: Molecular mechanisms, diagnosis and targeted therapy. Cancer Lett. 2021;505:13\u201323.","journal-title":"Cancer Lett"},{"key":"2876_CR20","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-06-2659","volume":"13","author":"D Palmieri","year":"2007","unstructured":"Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin Cancer Res. 2007;13:1656\u201362.","journal-title":"Clin Cancer Res"},{"key":"2876_CR21","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","volume":"64","author":"CN Sternberg","year":"1989","unstructured":"Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448\u201358.","journal-title":"Cancer."},{"key":"2876_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000019622","volume":"33","author":"R Dhote","year":"1998","unstructured":"Dhote R, Beuzeboc P, Thiounn N, et al. High incidence of brain metastases in patients treated with an M-VAC regimen for advanced bladder cancer. Eur Urol. 1998;33:392\u20135.","journal-title":"Eur Urol"},{"key":"2876_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/2152-7806.99172","volume":"3","author":"JM Sarmiento","year":"2012","unstructured":"Sarmiento JM, Wi MS, Piao Z, Stiner ES. Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: case report and literature review. Surg Neurol Int. 2012;3:82.","journal-title":"Surg Neurol Int"},{"key":"2876_CR24","first-page":"407","volume":"73","author":"G Rosiello","year":"2020","unstructured":"Rosiello G, Palumbo C, Deuker M, et al. Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Cent European J Urol. 2020;73:407\u201315.","journal-title":"Cent European J Urol"},{"key":"2876_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00066-010-2159-5","volume":"186","author":"E Fokas","year":"2010","unstructured":"Fokas E, Henzel M, Engenhart-Cabillic R. A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. Strahlenther Onkol. 2010;186:565\u201371.","journal-title":"Strahlenther Onkol"},{"key":"2876_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clineuro.2011.10.042","volume":"114","author":"D Rades","year":"2012","unstructured":"Rades D, Kueter JD, Meyners T, et al. Single brain metastasis: resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. Clin Neurol Neurosurg. 2012;114:326\u201330.","journal-title":"Clin Neurol Neurosurg"},{"key":"2876_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00246-008-9256-6","volume":"29","author":"T G\u00fcnther","year":"2008","unstructured":"G\u00fcnther T, Schreiber C, Noebauer C, Eicken A, Lange R. Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: a 30-year review. Pediatr Cardiol. 2008;29:1071\u20136.","journal-title":"Pediatr Cardiol"},{"key":"2876_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/jcp.2005.035105","volume":"60","author":"R Bussani","year":"2007","unstructured":"Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. J Clin Pathol. 2007;60:27\u201334.","journal-title":"J Clin Pathol"},{"key":"2876_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12885-018-4070-x","volume":"18","author":"I Burazor","year":"2018","unstructured":"Burazor I, Aviel-Ronen S, Imazio M, et al. Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment. BMC Cancer. 2018;18:202.","journal-title":"BMC Cancer"},{"key":"2876_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5","volume":"65","author":"EC Klatt","year":"1990","unstructured":"Klatt EC, Heitz DR. Cardiac metastases. Cancer. 1990;65:1456\u20139.","journal-title":"Cancer."},{"key":"2876_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10147-007-0749-8","volume":"13","author":"A Al-Mamgani","year":"2008","unstructured":"Al-Mamgani A, Baartman L, Baaijens M, de Pree I, Incrocci L, Levendag PC. Cardiac metastases. Int J Clin Oncol. 2008;13:369\u201372.","journal-title":"Int J Clin Oncol"},{"key":"2876_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-019-0662-1","volume":"20","author":"TJ Poterucha","year":"2019","unstructured":"Poterucha TJ, Kochav J, O'Connor DS, Rosner GF. Cardiac tumors: Clinical presentation, diagnosis, and management. Curr Treat Options in Oncol. 2019;20:66.","journal-title":"Curr Treat Options in Oncol"},{"key":"2876_CR33","first-page":"205","volume":"111","author":"A Hoffmeier","year":"2014","unstructured":"Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Cardiac tumors--diagnosis and surgical treatment. Dtsch Arztebl Int. 2014;111:205\u201311.","journal-title":"Dtsch Arztebl Int"},{"key":"2876_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/annonc\/mdh086","volume":"15","author":"K Reynen","year":"2004","unstructured":"Reynen K, K\u00f6ckeritz U, Strasser RH. Metastases to the heart. Ann Oncol. 2004;15:375\u201381.","journal-title":"Ann Oncol"},{"key":"2876_CR35","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIRCEP.110.961193","volume":"4","author":"M Casella","year":"2011","unstructured":"Casella M, Carbucicchio C, Dello Russo A, et al. Radiofrequency catheter ablation of life-threatening ventricular arrhythmias caused by left ventricular metastatic infiltration. Circ Arrhythm Electrophysiol. 2011;4:e7\u201310.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2876_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/0003-4975(91)91241-M","volume":"52","author":"A Miralles","year":"1991","unstructured":"Miralles A, Bracamonte L, Soncul H, et al. Cardiac tumors: clinical experience and surgical results in 74 patients. Ann Thorac Surg. 1991;52:886\u201395.","journal-title":"Ann Thorac Surg"},{"key":"2876_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1378\/chest.117.1.287","volume":"117","author":"E Kotani","year":"2000","unstructured":"Kotani E, Kiuchi K, Takayama M, et al. Effectiveness of transcoronary chemoembolization for metastatic right ventricular tumor derived from hepatocellular carcinoma. Chest. 2000;117:287\u20139.","journal-title":"Chest."},{"key":"2876_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/fon-2021-0795","volume":"18","author":"W Li","year":"2021","unstructured":"Li W, Jiang J, Huang L, Long F. Efficacy of PD-1\/L1 inhibitors in brain metastases of non-small-cell lung cancer: Pooled analysis from seven randomized controlled trials. Future Oncol. 2021;18:403\u201312.","journal-title":"Future Oncol"},{"key":"2876_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67:1079\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"2876_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell. 2015;28:285\u201395.","journal-title":"Cancer Cell"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02876-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:03:26Z","timestamp":1671415406000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2876"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02876-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient was diagnosed with bladder cancer, and after accepting standard first-line chemotherapy based on platinum, the cancer metastasized. According to China\u2019s National Medical Products Administration (NMPA) in 2020, tislelizumab can be used for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have failed to respond to first-line chemotherapy. As a result, tislelizumab administration is reasonable and appropriate in this patient\u2019s situation, without exceeding the drug\u2019s indication, and does not require prior approval from the ethics committee. In addition, we have obtained the patient\u2019s consent before using tislelizumab. Meanwhile, we have reorganized the case presentation and now have a better understanding of the patient\u2019s condition.Written informed consent was obtained from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data published here are under the consent for publication. Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}